Abstract

Nintedanib, a receptor tyrosine kinase (RTK) inhibitor has been developed as therapeutics for idiopathic pulmonary fibrosis and non-small lung cancer. We found that the expression levels of RTK, especially VEGFR1 is increased in skin biopsies of dermatitis patients from multiple independent datasets. Moreover, VEGFR1 is highly expressed by infiltrated cells in dermis from oxazolone (OXA) treated mice. Interestingly, nintedanib alleviates dermatitis symptom in OXA-induced animal model. Especially, levels of epidermis thickness, infiltrated immune cells including mast cells and eosinophils were decreased from mice cotreated with nintedanib and OXA compared with OXA treated mice. Moreover, serum IgE and Th2 cytokines including IL-4 and IL-13 were decreased by nintedanib treatment. These results suggest an evidence that nintedanib alleviates animal model of dermatitis.

Details

Title
Nintedanib ameliorates animal model of dermatitis
Author
Min-Jeong, Heo 1 ; Lee, Chanmi 1 ; Choi Soo Young 1 ; Choi, Yeong Min 1 ; An In-sook 1 ; Bae Seunghee 2   VIAFID ORCID Logo  ; An Sungkwan 2 ; Jung, Jin Hyuk 3   VIAFID ORCID Logo 

1  GeneCellPharm Corporation, Korea Institute of Dermatological Science, Seoul, South Korea 
2  Konkuk University, Research Institute for Molecular-Targeted Drugs, Department of Cosmetics Engineering, Seoul, South Korea (GRID:grid.258676.8) (ISNI:0000 0004 0532 8339) 
3  GeneCellPharm Corporation, Korea Institute of Dermatological Science, Seoul, South Korea (GRID:grid.258676.8) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41598-020-61424-1
ProQuest document ID
2376199057
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.